Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

Bibliographic Details
Main Authors:	Xueyan Wang, Xiaowei Liu, Willy Hugo, Lu Si, Hubing Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Immunology
Subjects:	immune checkpoint blockade (ICB) melanoma immune checkpoint inhibitors (ICIs) biomarker immune-related adverse events (irAEs) combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1065937/full

Similar Items

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
by: Shuming Chen, et al.
Published: (2024-03-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)

Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis
by: Naoki Hamada, et al.
Published: (2021-12-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
by: Vasiliki Nikolaou, et al.
Published: (2023-03-01)

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
by: Lærke K. Tolstrup, et al.
Published: (2022-01-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
by: Simona Coniac, et al.
Published: (2023-05-01)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
by: Yusha Wang, et al.
Published: (2023-11-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
by: Elisa Longhitano, et al.
Published: (2023-03-01)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Betul Ibis, et al.
Published: (2023-06-01)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
by: Jing Xiang, et al.
Published: (2023-12-01)

A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
by: Patricia Iranzo, et al.
Published: (2022-05-01)

Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options
by: Eveline Daetwyler, et al.
Published: (2023-10-01)

Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
by: Hua Zhu, et al.
Published: (2022-07-01)

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
by: Hongen Kang, et al.
Published: (2023-08-01)

PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
by: Yan Gu, et al.
Published: (2023-01-01)

Rapidly progressing dyspnea and retiform purpura
by: Bianca Y. Kang, MD, et al.
Published: (2022-12-01)

Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
by: Almog Shalit, et al.
Published: (2023-01-01)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
by: Adrian Chye, et al.
Published: (2022-07-01)

Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature
by: Xuewei Li, et al.
Published: (2022-09-01)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
by: Mona A. Marie, et al.
Published: (2022-12-01)

Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
by: Guang-Long Ma, et al.
Published: (2023-04-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
by: Zhifei Gao, et al.
Published: (2023-02-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
by: Mitchell S. von Itzstein, et al.
Published: (2024-04-01)

Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review
by: Dandan Geng, et al.
Published: (2022-08-01)

A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma
by: Satoshi Tanaka, et al.
Published: (2020-01-01)

Fever of unknown origin associated with immune checkpoint inhibitors
by: Xu Tong, et al.
Published: (2024-03-01)

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
by: Lisa Yang, et al.
Published: (2024-04-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
by: Chiao-En Wu, et al.
Published: (2020-10-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
by: Shangqin Sun, et al.
Published: (2021-04-01)

Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review
by: Haishan Wei, et al.
Published: (2024-01-01)